Who Optimizes SG&A Costs Better? Catalent, Inc. or Amneal Pharmaceuticals, Inc.

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Catalent, Inc. and Amneal Pharmaceuticals, Inc. have been on this journey since 2014. Over the years, Catalent has consistently outpaced Amneal in SG&A spending, with a peak of approximately $935 million in 2024, reflecting a 180% increase from 2014. In contrast, Amneal's SG&A expenses grew by about 400% over the same period, reaching around $430 million in 2023. This disparity highlights Catalent's aggressive expansion strategy, while Amneal's more conservative approach suggests a focus on cost efficiency. However, the absence of Amneal's 2024 data leaves room for speculation. As the industry evolves, these trends offer valuable insights into each company's strategic priorities and financial health.